<?xml version='1.0' encoding='utf-8'?>
<document id="26170788"><sentence text="Stevens-Johnson Syndrome triggered by a combination of clobazam, lamotrigine and valproic acid in a 7-year-old child."><entity charOffset="55-63" id="DDI-PubMed.26170788.s1.e0" text="clobazam" /><entity charOffset="65-76" id="DDI-PubMed.26170788.s1.e1" text="lamotrigine" /><entity charOffset="81-94" id="DDI-PubMed.26170788.s1.e2" text="valproic acid" /><pair ddi="false" e1="DDI-PubMed.26170788.s1.e0" e2="DDI-PubMed.26170788.s1.e0" /><pair ddi="false" e1="DDI-PubMed.26170788.s1.e0" e2="DDI-PubMed.26170788.s1.e1" /><pair ddi="false" e1="DDI-PubMed.26170788.s1.e0" e2="DDI-PubMed.26170788.s1.e2" /><pair ddi="false" e1="DDI-PubMed.26170788.s1.e1" e2="DDI-PubMed.26170788.s1.e1" /><pair ddi="false" e1="DDI-PubMed.26170788.s1.e1" e2="DDI-PubMed.26170788.s1.e2" /></sentence><sentence text="Stevens-Johnson Syndrome (SJS) and toxic epidermal necrolysis (TEN) are diseases within the spectrum of severe cutaneous adverse reactions affecting skin and mucous membranes" /><sentence text=" Antiepileptic drugs (AEDs) are used in combination, leading to potential pharmacokinetic or pharmacodynamic interactions, causing more adverse effects than might occur when the AED is taken as monotherapy" /><sentence text=" Here, we report a rare case of SJS triggered by a combination of clobazam, lamotrigine and valproic acid in a 7-year-old boy"><entity charOffset="66-74" id="DDI-PubMed.26170788.s4.e0" text="clobazam" /><entity charOffset="76-87" id="DDI-PubMed.26170788.s4.e1" text="lamotrigine" /><entity charOffset="92-105" id="DDI-PubMed.26170788.s4.e2" text="valproic acid" /><pair ddi="false" e1="DDI-PubMed.26170788.s4.e0" e2="DDI-PubMed.26170788.s4.e0" /><pair ddi="false" e1="DDI-PubMed.26170788.s4.e0" e2="DDI-PubMed.26170788.s4.e1" /><pair ddi="false" e1="DDI-PubMed.26170788.s4.e0" e2="DDI-PubMed.26170788.s4.e2" /><pair ddi="false" e1="DDI-PubMed.26170788.s4.e1" e2="DDI-PubMed.26170788.s4.e1" /><pair ddi="false" e1="DDI-PubMed.26170788.s4.e1" e2="DDI-PubMed.26170788.s4.e2" /></sentence><sentence text=" Because of inadequate seizure control, lorazepam was replaced with clobazam"><entity charOffset="40-49" id="DDI-PubMed.26170788.s5.e0" text="lorazepam" /></sentence><sentence text=" Four weeks after the addition of clobazam, the patient developed SJS with a generalized rash, fever, with liver and kidney involvement, and eosinophilia one week after the initiation of treatment"><entity charOffset="34-42" id="DDI-PubMed.26170788.s6.e0" text="clobazam" /></sentence><sentence text=" All antiepileptic drugs were discontinued, and intravenous methylprednisolone, prophylactic systemic antibiotics, intravenous fluid supplement, antipyretic, special wound care, and supportive medical care for SJS were administered"><entity charOffset="60-78" id="DDI-PubMed.26170788.s7.e0" text="methylprednisolone" /></sentence><sentence text=" He was discharged in a stable condition on the 18th day" /><sentence text=" Our case suggests that a drug-drug interaction between valproate, lamotrigine and clobazam contributed to the development of SJS"><entity charOffset="56-65" id="DDI-PubMed.26170788.s9.e0" text="valproate" /><entity charOffset="67-78" id="DDI-PubMed.26170788.s9.e1" text="lamotrigine" /><entity charOffset="83-91" id="DDI-PubMed.26170788.s9.e2" text="clobazam" /><pair ddi="false" e1="DDI-PubMed.26170788.s9.e0" e2="DDI-PubMed.26170788.s9.e0" /><pair ddi="false" e1="DDI-PubMed.26170788.s9.e0" e2="DDI-PubMed.26170788.s9.e1" /><pair ddi="false" e1="DDI-PubMed.26170788.s9.e0" e2="DDI-PubMed.26170788.s9.e2" /><pair ddi="false" e1="DDI-PubMed.26170788.s9.e1" e2="DDI-PubMed.26170788.s9.e1" /><pair ddi="false" e1="DDI-PubMed.26170788.s9.e1" e2="DDI-PubMed.26170788.s9.e2" /></sentence><sentence text=" When the clobazam was added to valproic acid and lamotrigine co-medication, the lamotrigine dose should have been decreased"><entity charOffset="10-18" id="DDI-PubMed.26170788.s10.e0" text="clobazam" /><entity charOffset="32-45" id="DDI-PubMed.26170788.s10.e1" text="valproic acid" /><entity charOffset="50-61" id="DDI-PubMed.26170788.s10.e2" text="lamotrigine" /><entity charOffset="81-92" id="DDI-PubMed.26170788.s10.e3" text="lamotrigine" /><pair ddi="false" e1="DDI-PubMed.26170788.s10.e0" e2="DDI-PubMed.26170788.s10.e0" /><pair ddi="false" e1="DDI-PubMed.26170788.s10.e0" e2="DDI-PubMed.26170788.s10.e1" /><pair ddi="false" e1="DDI-PubMed.26170788.s10.e0" e2="DDI-PubMed.26170788.s10.e2" /><pair ddi="false" e1="DDI-PubMed.26170788.s10.e0" e2="DDI-PubMed.26170788.s10.e3" /><pair ddi="false" e1="DDI-PubMed.26170788.s10.e1" e2="DDI-PubMed.26170788.s10.e1" /><pair ddi="false" e1="DDI-PubMed.26170788.s10.e1" e2="DDI-PubMed.26170788.s10.e2" /><pair ddi="false" e1="DDI-PubMed.26170788.s10.e1" e2="DDI-PubMed.26170788.s10.e3" /><pair ddi="false" e1="DDI-PubMed.26170788.s10.e2" e2="DDI-PubMed.26170788.s10.e2" /><pair ddi="false" e1="DDI-PubMed.26170788.s10.e2" e2="DDI-PubMed.26170788.s10.e3" /></sentence><sentence text=" " /><sentence text="La syndrome de Stevens-Johnson (SJS) et la nécrolyse épidermique toxique sont des maladies dans le spectre de réactions cutanées graves affectant la peau et les muqueuses" /><sentence text=" Les médicaments antiépileptiques sont utilisés en combinaison, et ceci peut provoquer des effets indésirables" /><sentence text=" Ici, nous rapportons un cas rare de SJS déclenché par une combinaison de clobazam, la lamotrigine et l’acide valproïque chez un garçon de 7 ans"><entity charOffset="87-98" id="DDI-PubMed.26170788.s14.e0" text="lamotrigine" /></sentence><sentence text=" En raison de l’ insuffisante maîtrise des crises, le lorazépam a été utilisé avec le clobazam" /><sentence text=" Quatre semaines après l’ajout de clobazam, le patient a développé SJS avec une éruption cutanée généralisée, de la fièvre" /><sentence text=" Il y avait la participation de la foie et les reins, et une éosinophilie, une semaine après le début du traitement" /><sentence text=" Tous les médicaments antiépileptiques ont été abandonnées, et la méthylprednisolone intraveineuse, des antibiotiques systémiques prophylactiques, supplément de liquide par voie intraveineuse, antipyrétique, les soins des plaies spécial, et de soutien pour les soins médicaux ont été administrés" /><sentence text=" Il a été libéré dans un état stable la 18ème journée" /><sentence text=" Notre cas suggère qu’une interaction médicamenteuse entre le valproate, la lamotrigine et clobazam ait contribué au développement de SJS"><entity charOffset="62-71" id="DDI-PubMed.26170788.s20.e0" text="valproate" /><entity charOffset="76-87" id="DDI-PubMed.26170788.s20.e1" text="lamotrigine" /><pair ddi="false" e1="DDI-PubMed.26170788.s20.e0" e2="DDI-PubMed.26170788.s20.e0" /><pair ddi="false" e1="DDI-PubMed.26170788.s20.e0" e2="DDI-PubMed.26170788.s20.e1" /></sentence><sentence text=" Lorsque le clobazam a été ajouté à l’acide valproïque et la lamotrigine, la dose de lamotrigine aurait dû être diminué"><entity charOffset="61-72" id="DDI-PubMed.26170788.s21.e0" text="lamotrigine" /><entity charOffset="85-96" id="DDI-PubMed.26170788.s21.e1" text="lamotrigine" /><pair ddi="false" e1="DDI-PubMed.26170788.s21.e0" e2="DDI-PubMed.26170788.s21.e0" /><pair ddi="false" e1="DDI-PubMed.26170788.s21.e0" e2="DDI-PubMed.26170788.s21.e1" /></sentence><sentence text="" /></document>